MCID: OST032
MIFTS: 33

Osteofibrous Dysplasia malady

Rare diseases, Bone diseases categories

Aliases & Classifications for Osteofibrous Dysplasia

About this section
Sources:
45NIH Rare Diseases, 47Novoseek
See all sources

Aliases & Descriptions for Osteofibrous Dysplasia:

Name: Osteofibrous Dysplasia 45 47
Intracortical Fibrous Dysplasia 45
 
Jaffe-Campanacci Syndrome 45
Ossifying Fibroma 45


Classifications:



Summaries for Osteofibrous Dysplasia

About this section
MalaCards based summary: Osteofibrous Dysplasia, also known as intracortical fibrous dysplasia, is related to fibroma and adenoma. An important gene associated with Osteofibrous Dysplasia is SPARC (Secreted Protein, Acidic, Cysteine-Rich (Osteonectin)), and among its related pathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Cytoskeleton remodeling Neurofilaments. Affiliated tissues include bone, and related mouse phenotypes are skeleton and tumorigenesis.

Related Diseases for Osteofibrous Dysplasia

About this section

Diseases related to Osteofibrous Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 148)
idRelated DiseaseScoreTop Affiliating Genes
1fibroma31.3BGLAP, SPARC
2adenoma30.6MUC1, VIM
3epulis30.4KRT1, MUC1, VIM
4juvenile ossifying fibroma11.1
5sinusitis10.8
6fibromatosis multiple non ossifying10.6
7ossifying fibroma10.6
8pyogenic granuloma10.6
9fibrous dysplasia10.5
10hyperparathyroidism10.5
11familial ossifying fibroma10.5
12gingivitis10.4
13neurofibromatosis, type 110.4
14neurofibromatosis10.4
15hyperparathyroidism-jaw tumor syndrome10.4
16chondrosarcoma10.4
17mastoiditis10.4
18periodontitis10.4
19monostotic fibrous dysplasia10.4
20mccune-albright syndrome, somatic, mosaic10.3
21pseudoarthrosis10.3
22retromolar area cancer10.3BGLAP, SPARC
23uterine corpus adenofibroma10.3NF1, SPARC
24interstitial myocarditis10.3BGLAP, SPP1
25retroperitoneal liposarcoma10.3SPP1, VIM
26caffey disease10.3BGLAP, CD36
27osteogenesis imperfecta, type iv10.2CD36, SPARC
28orbit embryonal rhabdomyosarcoma10.2MUC1, VIM
29lymphangiosarcoma10.2MUC1, VIM
30odontoma10.2CD36, VIM
31thyroid carcinoma with thyrotoxicosis10.2MUC1, VIM
32lung oat cell carcinoma10.2MUC1, VIM
33absence of fingerprints congenital milia10.2MUC1, VIM
34malignant teratocarcinosarcoma10.2MUC1, VIM
35ophthalmia neonatorum10.2MUC1, VIM
36juvenile macular degeneration and hypotrichosis10.2NF1, VIM
37portal hypertension10.2MUC1, VIM
38differentiating neuroblastoma10.2MUC1, VIM
39epithelioid cell synovial sarcoma10.2MUC1, VIM
40clivus chordoma10.2MUC1, VIM
41paralytic poliomyelitis10.2MUC1, VIM
42basal cell carcinoma 710.2MUC1, VIM
43vulvar nodular hidradenoma10.2MUC1, VIM
44subependymal giant cell astrocytoma10.2MUC1, VIM
45pediatric cns choriocarcinoma10.2MUC1, VIM
46osteogenesis imperfecta, type iii10.2BGLAP, CD36
47primary hypertrophic osteoarthropathy10.2MUC1, VIM
48hand dermatosis10.2MUC1, VIM
49anaplastic ganglioglioma10.2MUC1, VIM
50spindle cell liposarcoma10.2MUC1, VIM

Graphical network of the top 20 diseases related to Osteofibrous Dysplasia:



Diseases related to osteofibrous dysplasia

Symptoms for Osteofibrous Dysplasia

About this section

Drugs & Therapeutics for Osteofibrous Dysplasia

About this section

Drugs for Osteofibrous Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Etidronic acidapprovedPhase 2, Phase 3407414-83-73305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
 
CID3305
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronate disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
2DiphosphonatesPhase 2, Phase 3369
3risedronic acidPhase 2, Phase 397
4Calcium, DietaryPhase 2, Phase 33529
5
Anastrozoleapproved, investigationalPhase 2252120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
6
TestolactoneapprovedPhase 24968-93-413769
Synonyms:
(4AS,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-F]chromene-2,8(4bh)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
.DELTA.1-Dehydrotestolactone
.DELTA.1-Dehydrotestololactone
.DELTA.1-Testololactone
1 Dehydrotestolactone
1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone
1,2-Dehydrotestololactone
1,2-Didehydrotestololactone
1,2-didehydrotestololactone
1-Dehydrotestolactone
1-Dehydrotestololactone
1-dehydrotestololactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI)
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione
17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione
2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
968-93-4
AC1L22FS
Bristol Myers Squibb Brand of Testolactone
Bristol-Myers Squibb Brand of Testolactone
C02197
C19H24O3
CHEBI:9460
CHEMBL1571
CID13769
D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione
D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione
 
D00153
D013738
DB00894
Delta(1)-testololactone
Delta-1-testololactone
EINECS 213-534-6
Fludestrin
HSDB 3255
LMST02020084
LS-102968
MolPort-004-286-011
NCI60_001908
NSC 23759
NSC-12173
NSC23759
SQ 9538
SQ-9538
TESLAC (TN)
Teolit
Teslac
Teslak
Testolacton
Testolactona
Testolactona [INN-Spanish]
Testolactone
Testolactone (USP/INN)
Testolactone [USAN:INN]
Testolactonum
Testolactonum [INN-Latin]
Testolattone
Testolattone [DCIT]
Testolattone [Dcit]
UNII-6J9BLA949Q
ZINC04081771
delta(1)-Dehydrotestolactone
delta(1)-Testolactone
delta(1)-Testololactone
7
AlendronateapprovedPhase 2153121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
66376-36-1
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
Alendronate
Alendronate Sodium
 
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
Binosto
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
8
Fulvestrantapproved, investigationalPhase 2157129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
 
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
SID29215034
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
9
Letrozoleapproved, investigationalPhase 1326112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
10
Histamine Phosphateapproved85251-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
11
histamine85275614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
2Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneRecruitingNCT00445575Phase 2, Phase 3
3Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001728Phase 2
4Testolactone for the Treatment of Girls With LHRH Resistant Precocious PubertyCompletedNCT00001181Phase 2
5Arimidex in McCune Albright SyndromeCompletedNCT00055302Phase 2
6TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONERecruitingNCT01791842Phase 2
7Faslodex in McCune Albright SyndromeActive, not recruitingNCT00278915Phase 2
8Effects of Letrozole on Precocious Puberty Due to McCune Albright SyndromeCompletedNCT00006174Phase 1
9Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright SyndromeCompletedNCT00001973
10Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001851
11The Influence of Bisphosphonates in the Oral Cavity in ChildrenCompletedNCT00402064
12Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeRecruitingNCT00001727
13Histamine Responsiveness in McCune-Albright SyndromeRecruitingNCT00318097
14Natural History of Cherubism Observational StudyRecruitingNCT01916772
15Genetic and Functional Analysis of CherubismRecruitingNCT01630447

Search NIH Clinical Center for Osteofibrous Dysplasia

Genetic Tests for Osteofibrous Dysplasia

About this section

Anatomical Context for Osteofibrous Dysplasia

About this section

MalaCards organs/tissues related to Osteofibrous Dysplasia:

33
Bone

Animal Models for Osteofibrous Dysplasia or affiliated genes

About this section

MGI Mouse Phenotypes related to Osteofibrous Dysplasia:

38 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053908.8BMP2, CD36, GNAS, NF1, SPARC, SPP1
2MP:00020068.4MUC1, NF1, SPARC, SPP1, TGFB1
3MP:00053708.3CD36, GNAS, MUC1, NF1, SPP1, TGFB1
4MP:00053698.2CD36, GNAS, NF1, SPP1, TGFB1, VIM
5MP:00053918.1CD36, MUC1, NF1, SPARC, TGFB1, VIM
6MP:00053828.0BMP2, GNAS, KRT5, NF1, SPARC, TGFB1
7MP:00107717.3GNAS, KRT1, KRT5, MUC1, NF1, SPP1
8MP:00053857.2BMP2, CD36, GNAS, KRT1, NF1, SPP1
9MP:00053977.1CD36, GNAS, KRT1, NF1, SPARC, SPP1
10MP:00053787.1BMP2, CD36, GNAS, KRT1, NF1, SPP1
11MP:00053867.1CD36, GNAS, KRT5, NF1, SPARC, SPP1
12MP:00036316.9BMP2, CD36, GNAS, KRT1, NF1, SPP1
13MP:00053876.8CD36, GNAS, KRT1, NF1, SPARC, SPP1
14MP:00107686.5BMP2, CD36, GNAS, KRT1, KRT5, NF1
15MP:00053766.1BMP2, CD36, GNAS, KRT1, MUC1, NF1

Publications for Osteofibrous Dysplasia

About this section

Articles related to Osteofibrous Dysplasia:

(show top 50)    (show all 77)
idTitleAuthorsYear
1
Osteofibrous Dysplasia-like Adamantinoma of the Tibia in a 15-Year-Old Girl. (26447423)
2015
2
Imaging in osteofibrous dysplasia, osteofibrous dysplasia-like adamantinoma, and classic adamantinoma. (24199850)
2014
3
Congenital Osteofibrous Dysplasia Campanacci: Spontaneous Postbioptic Regression. (23774157)
2013
4
Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones. (21983933)
2012
5
Neonatal osteofibrous dysplasia associated with pathological tibia fracture: a case report and review of the literature. (21383639)
2012
6
Marginal excision and Ilizarov hemicallotasis for osteofibrous dysplasia of the tibia: a case report. (21164362)
2011
7
Osteofibrous dysplasia and adamantinoma. (20511441)
2010
8
Minimally invasive plate osteosynthesis for osteofibrous dysplasia of the tibia: a case report. (21187556)
2010
9
Congenital osteofibrous dysplasia of the tibia, associated with pseudoarthrosis of the ipsilateral fibula. (18946584)
2008
10
Treatment of osteofibrous dysplasia and associated lesions. (17594160)
2007
11
Frequent immunoexpression of TGF-beta1, FGF-2 and BMP-2 in fibroblast-like cells in osteofibrous dysplasia. (17273729)
2007
12
A classic adamantinoma arising from osteofibrous dysplasia-like adamantinoma in the lower leg: a case report and review of the literature. (16636523)
2006
13
Familial osteofibrous dysplasia. A case series. (16203897)
2005
14
Osteofibrous dysplasia and adamantinoma: correlation of proto-oncogene product and matrix protein expression. (14745727)
2004
15
Congenital (infantile) pseudarthrosis of the fibula associated with osteofibrous dysplasia. (15258702)
2004
16
Osteofibrous dysplasia treated with distraction osteogenesis: a report of two cases. (15449128)
2004
17
Classic adamantinoma with osteofibrous dysplasia-like foci and secondary aneurysmal bone cyst. (12574919)
2003
18
Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. (12679847)
2003
19
CD99 positive adamantinoma of the ulna with ipsilateral discrete osteofibrous dysplasia. (12616068)
2003
20
Comparative study of fibrous dysplasia and osteofibrous dysplasia: histopathological, immunohistochemical, argyrophilic nucleolar organizer region and DNA ploidy analysis. (11564214)
2001
21
Immunoexpression of neurofibromin, S-100 protein, and leu-7 and mutation analysis of the NF1 gene at codon 1423 in osteofibrous dysplasia. (11727265)
2001
22
Osteofibrous dysplasia of the ulna. (11793188)
2001
23
Osteofibrous dysplasia of the ulna. (11764436)
2001
24
A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalpha mutation at the Arg201 codon: polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues. (11272890)
2000
25
Osteofibrous dysplasia of the tibia: case report and review of the literature. (10709600)
1999
26
Treatment outcome of osteofibrous dysplasia. (9702669)
1998
27
Osteofibrous dysplasia-like adamantinoma of bone: a report of five cases with immunohistochemical and ultrastructural studies. (9712421)
1998
28
Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia. (9242211)
1997
29
Neonatal osteofibrous dysplasia: report of two cases. (8677152)
1996
30
Composition and posttranslational modification of individual collagen chains from osteosarcomas and osteofibrous dysplasias. (7635871)
1995
31
Clonal chromosomal abnormalities in osteofibrous dysplasia. Implications for histopathogenesis and its relationship with adamantinoma. (8156503)
1994
32
Relationship between osteofibrous dysplasia and adamantinoma. (7994967)
1994
33
Aggressive bone tumorous lesion in infancy: osteofibrous dysplasia of the tibia and fibula. (8376555)
1993
34
Osteofibrous dysplasia: clinicopathologic study of 80 cases. (8276381)
1993
35
Polyostotic lesions compatible with osteofibrous dysplasia. A case report. (8117510)
1993
36
Answer please. Osteofibrous dysplasia. (8290405)
1993
37
Osteofibrous dysplasia (ossifying fibroma of long bones). A report of four cases and review of the literature. (1563159)
1992
38
Osteofibrous dysplasia of the tibia treated by bracing. (1428320)
1992
39
Synovial sarcoma associated with osteofibrous dysplasia. A case report and review of the literature. (1510197)
1992
40
Juvenile intracortical adamantinoma of the tibia with predominant osteofibrous dysplasia-like features. (1724319)
1991
41
Congenital ossifying fibroma (osteofibrous dysplasia) of the tibia--a case report. (1749686)
1991
42
Case report 587: Adamantinoma of the tibia mimicking osteofibrous dysplasia. (2326657)
1990
43
MRI findings in osteofibrous dysplasia. (2607907)
1989
44
Morphologic diversity of long bone adamantinoma. The concept of differentiated (regressing) adamantinoma and its relationship to osteofibrous dysplasia. (2804923)
1989
45
Osteofibrous dysplasia. A report of two cases. (3201274)
1988
46
Osteofibrous dysplasia of the tibia and fibula. (3205593)
1988
47
Radiologic case study. Osteofibrous dysplasia. (3615297)
1987
48
Osteofibrous dysplasia (ossifying fibroma) of the tibia and fibula and adamantinoma. A case report. (6475846)
1984
49
Osteofibrous dysplasia of the tibia and fibula. (7204433)
1981
50
Osteofibrous dysplasia of long bones a new clinical entity. (1024109)
1976

Variations for Osteofibrous Dysplasia

About this section

Expression for genes affiliated with Osteofibrous Dysplasia

About this section
Search GEO for disease gene expression data for Osteofibrous Dysplasia.

Pathways for genes affiliated with Osteofibrous Dysplasia

About this section

GO Terms for genes affiliated with Osteofibrous Dysplasia

About this section

Cellular components related to Osteofibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet alpha granule membraneGO:003109210.5CD36, SPARC
2membrane-bounded vesicleGO:003198810.1BGLAP, SPARC, SPP1
3cell projectionGO:00429959.6BGLAP, SPP1, VIM
4intermediate filamentGO:00058829.5KRT1, KRT5, VIM
5extracellular regionGO:00055767.6BGLAP, BMP2, GNAS, SPARC, SPP1, TGFB1
6extracellular spaceGO:00056157.0BGLAP, BMP2, CD36, KRT1, MUC1, SPARC

Biological processes related to Osteofibrous Dysplasia according to GeneCards Suite gene sharing:

(show all 24)
idNameGO IDScoreTop Affiliating Genes
1response to gravityGO:000962910.5BGLAP, SPARC
2negative regulation of transcription factor import into nucleusGO:004299210.3CD36, NF1
3negative regulation of endothelial cell proliferationGO:000193710.3NF1, SPARC
4regulation of bone resorptionGO:004512410.2BGLAP, NF1
5regulation of angiogenesisGO:004576510.2KRT1, NF1
6ossificationGO:00015039.9BGLAP, SPARC, SPP1
7bone developmentGO:00603489.8BGLAP, GNAS, SPARC
8negative regulation of neuroblast proliferationGO:00074069.8NF1, TGFB1
9positive regulation of epithelial to mesenchymal transitionGO:00107189.7BMP2, TGFB1
10pathway-restricted SMAD protein phosphorylationGO:00603899.7BMP2, TGFB1
11positive regulation of odontogenesisGO:00424829.7BMP2, TGFB1
12platelet degranulationGO:00025769.6CD36, SPARC, TGFB1
13skeletal system developmentGO:00015019.6BGLAP, BMP2, GNAS
14response to vitamin DGO:00332809.5BGLAP, SPP1, TGFB1
15osteoblast differentiationGO:00016499.4BGLAP, BMP2, NF1, SPP1
16female pregnancyGO:00075659.3GNAS, MUC1, TGFB1
17wound healingGO:00420609.3NF1, SPARC, TGFB1
18negative regulation of gene expressionGO:00106299.2BMP2, CD36, TGFB1
19SMAD protein signal transductionGO:00603959.2BMP2, TGFB1, VIM
20inner ear developmentGO:00488399.2BMP2, SPARC, TGFB1
21cellular response to growth factor stimulusGO:00713638.9BGLAP, BMP2, SPARC, TGFB1
22response to hypoxiaGO:00016668.7BMP2, MUC1, NF1, TGFB1
23blood coagulationGO:00075968.4CD36, GNAS, SPARC, TGFB1
24extracellular matrix organizationGO:00301988.2BMP2, NF1, SPARC, SPP1, TGFB1

Molecular functions related to Osteofibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular matrix bindingGO:00508409.8SPARC, SPP1
2cytokine activityGO:00051258.9BMP2, SPP1, TGFB1
3structural molecule activityGO:00051988.6BGLAP, KRT1, KRT5, VIM

Sources for Osteofibrous Dysplasia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet